How to Fabricate Hyaluronic Acid for Ocular Drug Delivery DOI Creative Commons
Martha Kim, Mi-Young Jung, Doyeon Lee

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(12), P. 1604 - 1604

Published: Dec. 16, 2024

This review aims to examine existing research on the development of ocular drug delivery devices utilizing hyaluronic acid (HA). Renowned for its exceptional biocompatibility, viscoelastic properties, and ability enhance bioavailability, HA is a naturally occurring biopolymer. The discussed specific mechanisms by which enhances delivery, including prolonging residence time surfaces, facilitating controlled release, improving penetration through tissues. By focusing these unique functionalities, this highlights potential HA-based systems revolutionize treatment. Various fabrication techniques systems, hydrogels, nanoparticles, microneedles, are discussed, highlighting their respective advantages limitations. Additionally, explores clinical applications in treating range diseases, such as dry eye syndrome, glaucoma, retinal disorders, infections. comparing efficacy safety profiles with traditional methods, provide comprehensive understanding benefits challenges associated systems. Moreover, discusses current limitations future directions field, need standardized protocols, long-term biocompatibility studies, large-scale trials. insights advancements presented aim guide efforts, ultimately enhancing effectiveness patient outcomes.

Language: Английский

Hyaluronic Acid-Based Drug Delivery Systems for Cancer Therapy DOI Creative Commons
Ekaterina Pashkina, М. В. Быкова,

M. T. Berishvili

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(2), P. 61 - 61

Published: Jan. 7, 2025

In recent years, hyaluronic acid (HA) has attracted increasing attention as a promising biomaterial for the development of drug delivery systems. Due to its unique properties, such high biocompatibility, low toxicity, and modifiability, HA is becoming basis creation targeted systems, especially in field oncology. Receptors overexpressed subpopulations cancer cells, one them, CD44, recognized molecular marker stem cells. This review examines role receptors health tumors analyzes existing HA-based systems their use various types cancer. The new will bring opportunities challenges anti-cancer therapy.

Language: Английский

Citations

1
Role of TMEM230 in the Aberrant Glycosylation in Human Autoimmunity and Cancer DOI Creative Commons
Elena Angeli, Cinzia Cocola, Edoardo Abeni

et al.

Proteoglycan Research, Journal Year: 2025, Volume and Issue: 3(1)

Published: Jan. 1, 2025

ABSTRACT Alterations in glycoconjugate profiles are thought to promote changes cell‐to‐cell and cell‐to‐intracellular extracellular scaffold interactions human disease. The nearly unlimited number of “glycoforms” that may exist nature difficult study due glycosylation modifications being associated with non‐genome coded posttranscription post‐translation processes. Specific products generated by dependent on concentration sub‐cellular locations glycan synthesis processing enzymes. An indirect “high‐throughput” approach is characterize enzymes (hydrolases transferases) single cell sequencing all types tissue diseases. We previously identified TMEM230 as an endoplasmic reticulum (ER) protein regulates NOTCH glycoprotein receptor ligand signaling zebrafish blood vessel formation destructive remodeling capacities diverse including fibroblast, phagocytic immune system cells patients cancer or granulomatous systemic vasculitis autoimmune disorder. represents a paradigm mediated signal transduction supports the role modifications. ER initiates earliest steps synthesis, sorting, trafficking. As remodeling, Notch hallmarks disorders, we investigated whether aberrant expression was also rheumatoid arthritis (RA). In this current study, analysis supported downregulated synovial RA while were predominantly upregulated. contrast, upregulated high‐grade compared low‐grade gliomas it N‐linked (GlcNAc), glycosaminoglycan expression. Our collective results support glycan/glycoconjugate aggressive gliomas. therefore be therapeutic target marker for clinical treatment induced autoimmunity disorders cancer.

Language: Английский

Citations

1
The Tumor Stroma of Squamous Cell Carcinoma: A Complex Environment That Fuels Cancer Progression DOI Open Access

Alexandra Buruiană,

Bogdan‐Alexandru Gheban,

Ioana‐Andreea Gheban‐Roșca

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(9), P. 1727 - 1727

Published: April 29, 2024

The tumor microenvironment (TME), a complex assembly of cellular and extracellular matrix (ECM) components, plays crucial role in driving progression, shaping treatment responses, influencing metastasis. This narrative review focuses on the cutaneous squamous cell carcinoma (cSCC) stroma, highlighting its key constituents their dynamic contributions. We examine how significant changes within cSCC ECM—specifically, alterations fibronectin, hyaluronic acid, laminins, proteoglycans, collagens—promote cancer metastasis, drug resistance. composition TME is also explored, detailing intricate interplay cancer-associated fibroblasts (CAFs), mesenchymal stem cells (MSCs), endothelial cells, pericytes, adipocytes, various immune populations. These diverse players modulate development, angiogenesis, responses. Finally, we emphasize TME’s potential as therapeutic target. Emerging strategies discussed this include harnessing system (adoptive transfer, checkpoint blockade), hindering disrupting CAF activity, manipulating ECM components. approaches underscore vital that deciphering interactions advancing therapy. Further research illuminating these relationships will uncover new avenues for developing more effective treatments cSCC.

Language: Английский

Citations

7
Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies DOI Open Access

Zihao Wu,

J D Lu,

A. Van Loo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(6), P. 3141 - 3141

Published: March 8, 2024

Cluster of differentiation 44 (CD44), a cell surface adhesion molecule overexpressed in cancer stem cells, has been implicated chemoresistance. This scoping review, following PRISMA-ScR guidelines, systematically identified and evaluated clinical studies on the impact CD44 expression chemotherapy treatment outcomes across various types. The search encompassed PubMed (1985–2023) SCOPUS (1936–2023) databases, yielding total 12,659 articles, which 40 met inclusion criteria were included qualitative synthesis using predefined data extraction table. Data collected type, sample size, interventions, control, outcome, study variants isoforms, effect outcome. Most demonstrated an association between increased negative chemotherapeutic such as shorter overall survival, tumor recurrence, resistance to chemotherapy, indicating potential role upregulation chemoresistance patients. However, subset also reported non-significant relationships or conflicting results. In summary, this review highlighted breadth available literature investigating outcomes. Further research is required elucidate relationship aid clinicians managing CD44-positive

Language: Английский

Citations

6
Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer DOI Creative Commons

Kenichiro Ishikawa,

Hiroyuki Suzuki, Tomokazu Ohishi

et al.

Oncology Reports, Journal Year: 2024, Volume and Issue: 52(5)

Published: Aug. 29, 2024

CD44 is a type I transmembrane glycoprotein associated with poor prognosis in various solid tumors. Since plays critical role tumor development by regulating cell adhesion, survival, proliferation and stemness, it has been considered target for therapy. Anti‑CD44 monoclonal antibodies (mAbs) have developed applied to antibody‑drug conjugates chimeric antigen receptor‑T Anti-pan‑CD44 mAbs, C44Mab‑5 C44Mab‑46, which recognize both standard (CD44s) variant isoforms were previously developed. The present study generated mouse IgG2a version of the anti‑pan‑CD44 mAbs (5‑mG2a C44Mab‑46‑mG2a) evaluate antitumor activities against CD44‑positive cells. Both 5‑mG2a C44Mab‑46‑mG2a recognized CD44s‑overexpressed CHO‑K1 (CHO/CD44s) cells esophageal line (KYSE770) flow cytometry. Furthermore, could activate effector presence CHO/CD44s exhibited complement-dependent cytotoxicity KYSE770 administration significantly suppressed xenograft compared control IgG2a. These results indicate that exert cancers be promising therapeutic regimen

Language: Английский

Citations

6
UDP-glucose dehydrogenase supports autophagy-deficient PDAC growth via increasing hyaluronic acid biosynthesis DOI Creative Commons

Minghe Fan,

Sihan Huo,

Yuyao Guo

et al.

Cell Reports, Journal Year: 2024, Volume and Issue: 43(2), P. 113808 - 113808

Published: Feb. 1, 2024

Autophagy is an essential degradation and recycling process that maintains cellular homeostasis during stress or nutrient deprivation. However, certain types of tumors such as pancreatic cancers can circumvent autophagy inhibition to sustain growth. The mechanism autophagy-deficient ductal adenocarcinoma (PDAC) uses grow under deprivation poorly understood. Our data show in PDAC results UDP-glucose dehydrogenase (UGDH) degradation, which dependent on autophagic cargo receptor sequestosome 1 (p62). Moreover, we demonstrate accumulated UGDH indispensable for cells proliferation by promoting hyaluronic acid (HA) synthesis upon energy Using orthotopic mouse model PDAC, find HA targeting reduces tumor weight. Thus, the combined might be attractive strategy treatment.

Language: Английский

Citations

4
Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy DOI Open Access

Xiaqing Zhou,

Yaping Li, Shuangsuo Dang

et al.

World Journal of Hepatology, Journal Year: 2024, Volume and Issue: 16(2), P. 164 - 176

Published: Feb. 27, 2024

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poses a major challenge to global health due its high morbidity mortality. Conventional chemotherapy usually targeted patients with intermediate advanced stages, but it often ineffective suffers from problems such as multidrug resistance, rapid drug clearance, nonspecific targeting, side effects, low accumulation in tumor cells. In response these limitations, recent advances nanoparticle-mediated delivery technologies have emerged breakthrough approaches for treatment of HCC. This review focuses on nanoparticle-based systems, special attention various receptors overexpressed HCC These are key enhancing specificity efficacy nanoparticle represent new paradigm actively targeting combating We comprehensively summarize current understanding receptors, their role impact therapies By gaining deeper receptor-mediated mechanisms innovative therapies, more effective precise can be achieved.

Language: Английский

Citations

4
Role of Folate Receptor and CD44 in Targeting of Docetaxel and Paclitaxel Fabricated Conjugates for Efficient Cancer Therapy DOI Creative Commons
Amol Tatode, Pranav Agrawal, Jayshree Taksande

et al.

Journal of Medicine Surgery and Public Health, Journal Year: 2024, Volume and Issue: unknown, P. 100163 - 100163

Published: Dec. 1, 2024

Language: Английский

Citations

4
Preparation, characterization and in vitro evaluation of poly[lactic-co-(glycolic acid)] (PLGA) nanoparticles conjugated with depolymerized hyaluronic acid for drug delivery DOI

X. Janet Bertilla,

S. Rupachandra

Colloid & Polymer Science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Language: Английский

Citations

0
CD44 and Its Role in Solid Cancers – A Review: From Tumor Progression to Prognosis and Targeted Therapy DOI Creative Commons
João Martins Gama, Rui Caetano Oliveira

Frontiers in Bioscience-Landmark, Journal Year: 2025, Volume and Issue: 30(3)

Published: March 21, 2025

Cluster of differentiation 44 (CD44) is a transmembrane protein expressed in normal cells but overexpressed several types cancer. CD44 plays major role tumor progression, both locally and systemically, by direct interaction with the extracellular matrix, inducing tissue remodeling, activation different cellular pathways, such as Akt or mechanistic target rapamycin (mTOR), stimulation angiogenesis. As prognostic marker, has been identified player cancer stem (CSCs). CSCs phenotype are associated chemoresistance, alone combination other CSC markers, CD24 aldehyde dehydrogenase 1 (ALDH1), may be used for patient stratification. In therapy setting, explored viable target, directly indirectly. It revealed promising potential, paving way its future use clinical setting. Immunohistochemistry effectively detects overexpression, enabling patients to accurately selected surgery targeted anti-CD44 therapies. this review, we highlight properties CD44, expression tumoral tissues through immunohistochemistry potential treatment options. We also discuss significance marker added value therapeutic decision-making.

Language: Английский

Citations

0